Project Grant R18HS029431
- Federal Project Grant Award Summary Albert Einstein College of Medicine received a $183,558 Project Grant award effective March 1, 2026, through February 28, 2031, from the National Institute of Diabetes and Digestive and Kidney Diseases under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The award supports implementation and evaluation of T1D-PATCHY (Type 1 Diabetes-Promoting Access to Diabetes Technology with Community Health Workers for Youth), a...
- Federal Project Grant Award Summary The University of Michigan received a $779,978 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), effective September 6, 2025, with completion targeted for July 31, 2030. The research initiative addresses high rates of uncontrolled diabetes (elevated A1C levels) among individuals with unmet social needs such as food...
- Grant Award Summary New York University School of Medicine received a $847,498 Project Grant awarded on August 20, 2025, from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant funds the development and testing of AIMANAGE, an artificial intelligence-driven clinical decision support system and chatbot designed to improve patient adherence and reduce clinical...
- Federal Grant Award Summary The University of Michigan, through its Office of Research and Sponsored Projects, received a $780,220 Project Grant awarded on February 27, 2026, by the National Institute of Diabetes and Digestive and Kidney Diseases under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant funds a clinical optimization trial to develop and evaluate a scalable digital behavioral intervention for mitigating level 2 hypoglycemia (severe...
- Federal Project Grant Award Summary The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $295,494 Project Grant to the University of Illinois effective September 15, 2025 (through August 31, 2030) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). This award funds the ACCELERATED-T2D research initiative, which investigates the relationship between socioeconomic status (SES) and treatment intensification patterns in Type...
- Federal Project Grant Award Summary Cedars-Sinai Medical Center received a $125,250 Project Grant (R03) award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), effective February 18, 2026, through January 31, 2028. The award supports the Movement Over Virtual Reality (MOVR) project, which addresses physical inactivity among patients with prediabetes through...
- Federal Grant Award Summary Rush University Medical Center received a $942,000 Project Grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), awarded September 16, 2025, with completion targeted for August 31, 2028. The award funds development and feasibility testing of a primary care-based weight management program designed to address rapid weight regain following...
- Federal Project Grant Award Summary Icahn School of Medicine at Mount Sinai received a $361,250 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), effective July 1, 2025, with completion scheduled for June 30, 2028. The award funds a Phase 2 randomized, placebo-controlled crossover clinical trial investigating atomoxetine, an existing...
- Federal Project Grant Award Summary Scripps Health received a $165,541 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), effective September 15, 2025, with a completion date of July 31, 2030. This K01 Career Development Award supports Dr. San Diego's research to integrate continuous glucose monitoring (CGM) technology into diabetes self-management...
- Federal Grant Award Summary The Jaeb Center for Health Research Foundation, Inc. received a $2.34 million Project Grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), awarded September 3, 2025, with completion scheduled for August 31, 2028. The project, titled "Care Partner-Assisted Implementation of Patch Hybrid Closed Loop Insulin Delivery for Older Adults...
SINAI DIABETES CENTER - PROJECT SUMMARY SINAI CHICAGO (SINAI) IS ILLINOIS' LARGEST PRIVATE SAFETY-NET HEALTHCARE SYSTEM, SERVING PREDOMINANTLY LOW-INCOME COMMUNITIES OF COLOR WITH LARGE MEDICAID-ELIGIBLE POPULATIONS IN CHICAGO. IN RESPONSE TO HIGH DIABETES RATES AND COMMUNITY CALLS FOR COORDINATED, MULTIDISCIPLINARY DIABETES CARE, SINAI DESIGNED THE CENTER FOR DIABETES AND ENDOCRINOLOGY (THE CENTER) WHICH LAUNCHED IN 2020. THE CENTER USES A COMPREHENSIVE MODEL WITH STREAMLINED SERVICES TO ADDRESS THE FULL SPECTRUM OF PATIENT MEDICAL AND NON-MEDICAL NEEDS. WE PROPOSE A CONVERGENT MIXED-METHODS OPTIMIZATION STUDY TO DETERMINE THE APPROPRIATENESS AND FIDELITY OF THREE INTERVENTION COMPONENTS OF A TEAM- BASED CARE MODEL FOR PATIENTS SERVED BY THE CENTER TO DEFINE THE IDEAL SEQUENCE FOR IMPROVING PATIENT OUTCOMES. GROUNDED IN QUALITATIVE METHODOLOGY AND GUIDED BY A SEQUENTIAL MULTIPLE ASSIGNMENT RANDOMIZED TRIAL (SMART), WE PROPOSE EVALUATING THE APPROPRIATENESS OF NOVEL INTERVENTION ENHANCEMENTS (AIM 1); MEASURING FIDELITY OF NEW INTERVENTION ENHANCEMENTS (AIM 2); COMPARING THE EFFECTIVENESS AND DETERMINING OPTIMIZATION OF INTERVENTION ENHANCEMENTS (AIM 3). WE WILL EVALUATE AIM 1 VIA KEY STAKEHOLDER INTERVIEWS AND FOCUS GROUPS. WE WILL ANALYZE AIMS 2 AND 3 BY CONDUCTING DESCRIPTIVE STATISTICS ON ALL VARIABLES, GIVING SPECIAL ATTENTION TO OUTLIER VALUES. WE WILL ALSO RUN BIVARIATE AND MULTIVARIATE ANALYSES ACROSS VARIABLES OF INTEREST AND TIME POINTS TO DETERMINE THE OPTIMAL SEQUENCE OF INTERVENTION ACTIVITIES. WE WILL DISSEMINATE OUR LEARNINGS BROADLY TO KEY STAKEHOLDERS THROUGH COMMUNITY FORUMS, PEER-REVIEWED PUBLICATIONS AND PRESENTATIONS. OUR MULTI-DISCIPLINARY TEAM HAS A WEALTH OF EXPERIENCE IN HEALTH SERVICES PROGRAMMING AS WELL AS RESEARCH AND EVALUATION. WE PROPOSE A 3 YEAR, $1.5 MILLION PROJECT FROM MARCH 2023 TO FEBRUARY 2026.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $0 | 1/28/26 | ||
| Not listed | $475.4k | 3/19/25 | ||
| Not listed | $475.4k | 3/19/25 | ||
| Not listed | $500.0k | 4/9/24 | ||
| Not listed | $500.0k | 4/9/24 |